chrisvoncsefalvay/vaers-outcomes huggingface dataset:
nausea; warm to touch; soreness at the injection site; swelling at the injection site; redness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE JOINT WARMTH (warm to touch), INJECTION SITE PAIN (soreness at the injection site), INJECTION SITE SWELLING (swelling at the injection site), INJECTION SITE ERYTHEMA (redness at the injection site) and NAUSEA (nausea) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced INJECTION SITE JOINT WARMTH (warm to touch), INJECTION SITE PAIN (soreness at the injection site), INJECTION SITE SWELLING (swelling at the injection site) and INJECTION SITE ERYTHEMA (redness at the injection site). On 19-Jan-2021, the patient experienced NAUSEA (nausea). On 23-Jan-2021, NAUSEA (nausea) had resolved. At the time of the report, INJECTION SITE JOINT WARMTH (warm to touch), INJECTION SITE PAIN (soreness at the injection site), INJECTION SITE SWELLING (swelling at the injection site) and INJECTION SITE ERYTHEMA (redness at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. Treatment information was not reported.
Received DTaP, HPV and IPV afternoon of 9-19-08. Began that evening with fever to 103 and leg pain. Continued through 9-21-08. Evening of 9-21-08, leg noted to be swollen. Today (9-22-08) red area noted. Non tender. Prescribed Keflex 250mg BID x 7d. DTaP given in (R) thigh - area of pain and redness.
26FEB92 tc from mom that pt rt arm where yellow fever vax recvd is red in a circle the size of a quarter & has blisters; pt has also c/o h/a & arm stiff;  No MD vist;
Sore under arm pit couldn't raise it .  Although it has improved it still hurts.; Sore under arm pit couldn't raise it .; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration in the right arm on 27Feb2021 at 09:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as yes (unspecified). The patient had allergies to medications, food or other products (unspecified). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation. On 27Feb2021 at 09:00, the patient experienced sore under arm pit, couldn't raise it.  Although it had improved it still hurt. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sore under arm pit, couldn't raise it was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Information has been received from a medical assistant referring to an unspecified number of patients of unknown age and gender. There was no medical history or drug reaction/allergies reported. On unknown dates, the patients were vaccinated with improperly stored doses of MMR II (lot# L015282 with expired date 30-APR-2017, lot# L026550 with expired date 16-JUL-2017, therapy type: rHA, dose and route were unknown). No concomitant therapy was reported. No adverse effect was reported. Additional information has been requested.
redness, warmth and swelling to area of injection for 1-4 days post injection,swelling and redness improved on the 5th and 6th of Feb. Redness to left upper arm in V-shape pattern noted by patient 2/7/21. Soreness to left axillary region started approx. 6 days post injection
Typical muscle soreness lasted a couple days. Lingering headache off and on. Feeling of tiredness for a couple days. Tuesday started with brain fog. Thursday was more noticeable at work trying to perform normal tasks. Friday felt lightheaded and dizzy. Couldn?t focus and waves of anxiety with headache. Coworker mentioned my complexion was yellow and eyes were red. Feels faint and fell over but didn?t lose consciousness. Saturday felt lightheaded and still went to work and passed out at work. Today is Monday 10 days after vaccine. I can?t work or drive due to weakness, lightheaded and faint. I?m slow with speech and get confused very easily. Didn?t recognize my own kitchen at one point. Wasn?t sure where my bathroom was earlier. No appetite. Sharp pains randomly in my head.
About 2 inch square rash, red, burning sensation, tender skin, still getting worse after 1 week.
Patient walked out of the wellness room and passed out.  Patient's father was able to caught him.  Patient was awake when I stepped out of the pharmacy.  Patient stated he felt blurry.  Patient was able to walk normal when he left.
48 hour after: Body aches; 48 hour after: Headache; 48 hour after: Nausea; 48 hour after: Injection site pain; 48 hour after: Fatigue; 1 week after: severe bouts of vertigo throughout day, daily for about a week now; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01May2021 at 11:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to coconut. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram oxalate (LEXAPRO) and multivitamins (BAYER FLINTSTONES CHILDREN'S MULTIVITAMIN), both taken for an unknown indication on an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 10Apr2021 at 11:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. On 03May2021, 48 hours after vaccination, the patient experienced body aches, headache, nausea, injection site pain and fatigue. On an unknown date in May2021, one week after the vaccination, the patient experienced severe bouts of vertigo throughout day, daily for about a week till the time of this report. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches, headache, nausea, injection site pain, fatigue and bouts of vertigo throughout day, daily for about a week till the time of this report was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Tenderness; Pain; Little swollen in the injection site; Redness; Fever in the arm; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (Tenderness), VACCINATION SITE PAIN (Pain), VACCINATION SITE SWELLING (Little swollen in the injection site), VACCINATION SITE ERYTHEMA (Redness) and PYREXIA (Fever in the arm) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Jan-2021, the patient experienced TENDERNESS (Tenderness), VACCINATION SITE PAIN (Pain), VACCINATION SITE SWELLING (Little swollen in the injection site), VACCINATION SITE ERYTHEMA (Redness) and PYREXIA (Fever in the arm). At the time of the report, TENDERNESS (Tenderness), VACCINATION SITE PAIN (Pain), VACCINATION SITE SWELLING (Little swollen in the injection site) and PYREXIA (Fever in the arm) outcome was unknown and VACCINATION SITE ERYTHEMA (Redness) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment details not provided. Concomitant details not provided.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events and a causal relationship cannot be excluded. Further information has been requested.
p/vax pt exp firm mass around site 5 cm, inflamed & warm to elbow, heat & anti inflammation recommended
Dose received: 3; I had one hive on my butt cheek. Then woke up 2 mornings after shot with small hives under my eyes. On 3rd morning there were more hives under my eyes. The hive on my butt cheek is a little lower but still there.; Woke up 2 mornings after shot, my eye lids were slightly swollen. On 3rd morning, my eyelids were also still a little swollen.; This is a spontaneous report from a contactable reporter (Other healthcare professional). The reporter is the patient.  A 25-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 24Dec2021 at 15:15 (Lot number: 33130BA) at the age of 25 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication included: LARIN 24 FE taken for Birth control. Past drug history included: Bactrim, reaction: "Drug allergy", notes: Known allergies: Bactrim and Zithromax, reaction: "Drug allergy", notes: Known allergies: Zithromax. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot Number: EW0170, Anatomical Location: Left arm, Administration Time: 14:00, Route of Administration: Unknown), administration date: 21Apr2021, when the patient was 24 years old, for COVID-19 immunisation and Bnt162b2 (DOSE  2, SINGLE, Lot Number: EW0185, Anatomical Location: Left arm, Administration Time: 14:00, Route of Administration: Unknown), administration date: 12May2021, when the patient was 24 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 24Dec2021 at 15:15, outcome "unknown", described as "Dose received: 3"; URTICARIA (non-serious) with onset an unknown date in Dec2021, outcome "not recovered", described as "I had one hive on my butt cheek. Then woke up 2 mornings after shot with small hives under my eyes. On 3rd morning there were more hives under my eyes. The hive on my butt cheek is a little lower but still there"; SWELLING OF EYELID (non-serious) with onset an unknown date in Dec2021, outcome "not recovered", described as "Woke up 2 mornings after shot, my eye lids were slightly swollen. On 3rd morning, my eyelids were also still a little swollen". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of urticaria and swelling of eyelid.  Additional information: The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19 and the result was negative. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.
Information has been received from a nurse concerning an 11-12 year old female who was vaccinated with VARIVAX (Merck) (lot no., route and site of administration were not reported) 6-8 months ago.  At the same time the patient was vaccinated with GARDASIL (lot no., route and site of administration were not reported).  The vaccinations were given in the same arm.  The day after the patient received the vaccinations, the patient developed redness and swelling at the injection site.  It was reported that these events had an onset date of 6-8 months ago (approximately October 2007).  All symptoms resolved in a few days.  The patient sought unspecified medical attention.  This is one of several reports received from the same source.  Additional information has been requested.
Patient began having low fever after the vaccine.  THe following day at 10 her fevers were high.  Her skin color was off and I called the doctor's office because I was worried something strange was going on.  I told the nurse that I worried she was going to have a seizure-because of the way she was behaving.  I was told that fevers were normal after vaccinations.  Right before the seizure, patient became dazed and tired.  She then cuddled up with my sister, and went limp and was having difficulty breathing.  My sister called 911.  Patient was transported via ambulance to Hospital. She had two additional seizures a week from the date of the first seizure, 11/14/2012.  The second seizure took place at the doctor's office and the third at the Hospital.  From Hospital she was transported to another Hospital.
Body aches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Mar-2021, the patient experienced PAIN (Body aches). At the time of the report, PAIN (Body aches) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was unknown by the reporter. Treatment information was not provided.
Narrative: COVID infection following COVID vaccine series 03/09, Pfizer, dose #1 03/30, Pfizer, dose #2 08/18 pt cc: headache, myalgias, chills, diarrhea, fatigue, fever exposure: unknown 08/18 COVID swab, result: detected 08/19- 08/60 pt symptoms continue
Patient was under the age of 18 during administration., No side effects present Spoke with Mother of patient 8 days later and no side effects to date.
Patient developed erythema, moderate swelling and warmth at site of IM injection at the right thigh.  Prednisolone (15mg/5mL) sec per mouth every 3 hours for 4 days was prescription.  Complete resolution within 24-48 hours.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 71-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Oct2022 as dose 5 (booster), single (Lot number: GH9697) at the age of 71 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 02Feb2021 as dose 1, single (Lot number: EL9264), in left arm, on 23Feb2021 as dose 2, single (Lot number: EN6203), in left arm, on 08Oct2021 as dose 3 (booster), single (Lot number: FF2587), in left arm and on 01Apr2022 as dose 4 (booster), single (Lot number: FK9729), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Diabetes" (unspecified if ongoing); "Known allergies: wool" (unspecified if ongoing), notes: Known allergies: wool; "Known allergies: dust" (unspecified if ongoing), notes: Known allergies: dust; "Known allergies: mold" (unspecified if ongoing), notes: Known allergies: mold. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 03Jan2023 at 10:00, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (29Dec2022) Negative, notes: Tested negative on home test on 29Dec2022; (03Jan2023) Positive, notes: 03Jan2023; took a home test and it was positive for Covid. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical Information: Patient received the vaccine. Patient received other medications in 2 weeks. Antiviral details: Product: COVID 19 Treatment, Brand: Paxlovid, Treatment start date: 20Dec2022,Treatment stop date: 24Dec2022,Indication: Treatment of COVID-19.
pt recv vax 1AUG95 & 2AUG95 pt devel a fever blister on lip;pt recv 2nd dose of vax APR96;
24 post-vaccination patient began feeling severe stomach discomfort followed by 5 days of severe diarrhea that warranted an urgent care visit.; 24 post-vaccination patient began feeling severe stomach discomfort followed by 5 days of severe diarrhea that warranted an urgent care visit.; This is a spontaneous report from a contactable pharmacist. A 69-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: el9267) via intramuscular route of administration in the left arm on 18Feb2021 at 10:15 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included anticoagulant therapy. The patient had no known allergies to medications, food, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Feb2021 at 19:00, 24 post-vaccination the patient began feeling severe stomach discomfort followed by 5 days of severe diarrhea that warranted an urgent care visit. It was reported that the patient refused second vaccination in fear of similar reaction going forward. The events resulted in emergency room/department visit or urgent care. Therapeutic measures were taken as a result of the events and included treatment with fluids. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in 2021, the patient underwent COVID-19 test via nasal swab and the result was negative. The clinical outcome of the event 24 post-vaccination patient began feeling severe stomach discomfort followed by 5 days of severe diarrhea that warranted an urgent care visit was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Tinnitus-Mild, Additional Details: ear pain
Possible side effect; This spontaneous case was reported by a patient and describes the occurrence of ADVERSE EVENT (Possible side effect) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jun-2021, the patient experienced ADVERSE EVENT (Possible side effect). At the time of the report, ADVERSE EVENT (Possible side effect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment information was reported.
Nausea, dry heaving, pallor for about 5-10 minutes after vaccine, Pt was very nervous prior to vaccines and will have similar reactions when she is nervous (ex: dental work).
sweat; Flu like symptoms; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweat) and VOMITING (vomiting) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 10-Mar-2021, the patient experienced HYPERHIDROSIS (sweat) and VOMITING (vomiting). At the time of the report, HYPERHIDROSIS (sweat) and VOMITING (vomiting) outcome was unknown.            Treatment medications were not provided  Action taken with mRNA-1273 in response to the event was not applicable
Tightness in chest, visible tremors in hands, tightness in throat  Vital Signs: BP 174/104 HR 106 O2Sat 98  Skin Signs: Cool and dry, diaphoretic  Respiratory: Breath sound clear bilaterally, diminished but clear wheezing  Initial Treatment: Patient felt anxious, so took Xanax before calling for help. She called for attention and stated she had difficulty breathing, different from asthma. Stated she could feel her BP was high - has hx of this. Taken to triage.  11:35 AM  Vital Signs: 196/110 HR 106 O2Sat 98 Skin Signs: Clammy, diaphoretic  11:39 AM  Vital Signs: BP 178/102 HR 106 O2Sat 98 Follow up Treatment: EMS activated after first dose of Nifedipine  Discharged with ambulance
A patient who was 11 years old received a pediatric covid vaccine. He turned 12 in between getting his first and second dose. The second dose that he was administered was the pediatric vaccine which is acceptable according to the EUA. The patient's parent agreed to getting the pediatric vaccine instead of the adult dose prior to administration. No adverse event occured.
I developed a large ?lump? on the right side of my neck that was tender to touch. I saw my PCP who ordered a thyroid ultrasound, which showed multiple thyroid cysts, the largest was about 3 cm in diameter, which warranted a biopsy. I had that performed this week, with negative pa to log, but now I have to get serial ultrasounds of the cysts to ensure stability in the future. I have never had any thyroid or cyst issues in the past.
1:45 PM Patient was given 6 vaccinations and waited in waiting room following while sibling received vaccines. Left the office without any symptoms until 2:05 PM father returned inside from parking complaining patient felt dizzy. Patient was standing with support on sidewalk at time of assessment, Alert and oriented, speaking clearly but diaphoretic complaining of dizziness, lowered to ground with feet elevated, patient remained awake throughout and speaking to nurses and family, ice pack applied to back of neck, able to take sips of water, and instructed to take slow deep breaths. Patient recovered quickly after 5-10 minutes supine with legs elevated. BP 103/76, HR 75. Denies any SOB, no urticaria present, no discomfort in throat/tongue, no anaphylaxis. Patient reported feeling better, helped up by staff, and able to walk on his own, returned inside office to sit for another 15 minutes and cleared for departure after reporting feeling well with no signs of distress.
25 year old female went to ER after calling into COVID-19 triage line. Patient had 2nd COVID-19 vaccine at approximately 09:00 on 28 Jan and was experiencing headache, vomiting, coughing and 'itching' of the throat. ER released after 2 hours of observation after Benadryl and Tylenol were administered. Patient states her 'throat itching' is better and has no complaints of shortness of breath or coughing at this time. Pt talked in full sentences without noted gasping or pauses for breath during 4 minute conversation. Pt states she will return to work today (29 Jan).
Pt's mom noticed a quarter-sized raised, red welt around injection site.  It was hot to the touch, but pt. did not complain of pain.  There was some itching.  Pt. had no fever or any other symptoms.  24 hrs. after 1st onset of reaction, welt had grown bigger.  Pt. was treated with KEFLEX after Dx with cellulitis on left thigh.